Fertility Monitoring Product Secures £250k Injection

A Warwickshire-based manufacturer of fertility monitoring products has secured a £250,000 boost.

Fertility Focus has received the loan from MEIF through a £250,000 loan enabling it to invest in its staff, continue research and development while safeguarding against the impact of Covid-19.

The business secured the finance from The FSE Group Debt Finance Fund, part of the Midlands Engine Investment Fund (MEIF) and backed by the Coronavirus Business Interruption Loan Scheme (CBILS).

Established in 2005, Fertility Focus specialises in the manufacturing and marketing of fertility monitoring products designed to help women who are experiencing issues conceiving.

Chief executive Rob Milnes said: “Health statistics tell us around 12 million women in North America and Europe start out trying to conceive each year.

“Of these, 4 million end up trying to conceive for six months or more, with a further 2 million moving on each year into the clinical segment. Securing additional funding is a significant step towards continuing to support women and their partners through a highly emotional journey.

“We would like to extend our thanks to Paul, at the FSE Group, for taking us through the process of securing finance from CBILS and MEIF – enabling us to help the business to navigate the impact of Covid-19 which will help us through these difficult times, maintaining key staff whilst continuing with key research to help us develop our product offering.”

The FSE Group’s fund manager, Paul Lynam, added: “Rob Milnes and the team at Fertility Focus are driven by a commitment to help women understand their reproductive cycles in order to better inform why they may be experiencing difficulty in conceiving.

“The product is of particular relevance at the moment as the ability of individuals to visit IVF clinics during Covid-19 has been disrupted. It has been a pleasure to support Steve, Rob and the Fertility Focus team and we look forward to seeing what the future holds.”

Total
0
Shares
Previous Post

INVO Bioscience Moves into the European Fertility Market with Initial Orders of INVOcell (IVC) in Spain

Next Post

MyHealthChecked Gains £3m Investment to Fund Rapid Expansion

Related Posts

Subscribe to our newsletter!

Subscribe to our newsletter!